

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 1074309
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
				First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned R. Anderson
Sheet	1	of	11	Attorney Docket Number	034536-0920

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
RL	A1	2968557		Burgandt et al.	01/17/1961	
RL	A2	4002749		Rovnyak	01/11/1977	
RL	A3	4053613		Rovnyak et al.	10/11/1977	
RL	A4	4642309		Michel et al.	02/10/1987	
RL	A5	4826847		Michel et al.	05/02/1989	
RL	A6	5051417		Nadler et al.	09/24/1991	
RL	A7	5124347		Connor et al.	06/23/1992	
RL	A8	5196446		Levitzki et al.	03/23/1993	
RL	A9	5302606		Spada et al.	04/12/1994	
RL	A10	5322950		Sircar et al.	06/21/1994	
RL	A11	5374652		Buzzetti et al.	12/20/1994	
RL	A12	5382593		Le Baut et al.	01/17/1995	
RL	A13	5389661		Sircar et al.	02/14/1995	
RL	A14	5397787		Buzzetti et al.	03/14/1995	
RL	A15	5409949		Buzzetti et al.	04/25/1995	
RL	A16	5792783		Tang et al.	08/11/1998	
RL	A17	5834504		Tang et al.	11/10/1998	
RL	A18	5849710		Battistini et al.	12/15/1998	
RL	A19	5880141		Tang et al.	03/9/1999	

Examiner Signature		Date Considered	12/17/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 10/743909
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	2	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned R. Anderson
				Attorney Docket Number	034536-0920

U.S. PATENT DOCUMENTS					
		U.S. Patent Document			
<i>RL</i>	A20	5883113		Tang et al.	03/16/1999
<i>RL</i>	A21	5883116		Tang et al.	03/16/1999
<i>RL</i>	A22	5886020		Tang et al.	03/23/1999
<i>RA</i>	A23	6133305		Tang et al.	10/17/2000
<i>RL</i>	A24	6451838		Moon et al.	09/2002

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>RL</i>	A25	WO	91/13055			09/05/1991		
<i>RL</i>	A26	WO	92/07830			05/14/1992		
<i>RL</i>	A27	WO	92/20642			11/26/1992		
<i>RL</i>	A28	WO	93/01182			01/21/1993		
<i>RL</i>	A29	WO	94/14808			07/07/1994		
<i>RL</i>	A30	WO	95/01349			01/12/1995		
<i>RL</i>	A31	WO	95/17181			06/29/1995		
<i>RL</i>	A32	WO	96/00226			01/04/1996		
<i>RL</i>	A33	WO	96/16964			06/06/1996		
<i>RL</i>	A34	WO	96/22976			08/01/1995		
<i>RL</i>	A35	WO	96/32380			10/17/1996		
<i>RA</i>	A36	WO	96/40116			12/19/1996		

Examiner Signature	<i>Kelvin Doyle</i>	Date Considered	12/17/04
--------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned- 10174309
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	3	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned- 1626
				Examiner Name	Unassigned- R. Andruska
				Attorney Docket Number	034536-0920

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
R	A37	WO	97/25986			07/24/1997		
R	A38	WO	98/07695			02/26/98		
R	A39	WO	98/24432			6/11/98		
R	A40	WO	98/38984			9/11/98		
R	A41	WO	98/50356			11/12/98		
R	A42	WO	99/10325			3/4/99		
R	A43	WO	99/52869			10/21/99		
R	A44	WO	99/61422			12/2/99		
R	A45	WO	99/65869			12/23/99		
R	A46	WO	00/08202			2/17/00		
R	A47	WO	00/35906			6/22/00		
R	A48	WO	00/35908			6/22/00		
R	A49	WO	00/35909			6/22/00		
R	A50	WO	00/38519			7/6/00		
R	A51	WO	00/56709			9/28/00		
R	A52	WO	01/60814			8/23/01		
R	A53	WO	01//90104			11/29/01		
R	A54	DE	2159360			11/30/71		Trans.
R	A55	DE	2159361			11/30/71		Trans.

Examiner Signature		Date Considered	12/17/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 101743909
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	4	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned P. Anderson
				Attorney Docket Number	034536-0920

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PL	A56	DE	2159362			11/30/71		
PL	A57	DE	2159363			11/29/71		Trans.
PL	A58	DE	2321656			4/28/73		Trans.
PL	A59	DE	3426419			1/23/86		Trans.
PL	A60	EP	0252713			9/12/1990		
PL	A61	EP	0351213			1/17/90		
PL	A62	EP	0525472			2/3/93		
PL	A63	EP	0632102			1/4/95		Trans.
PL	A64	EP	0662473			7/12/95		
PL	A65	EP	0788890			8/13/97		
PL	A66	EP	0769947			5/2/97		
PL	A67	EP	0934931			8/11/99		
PL	A68	EP	1082305	A1		3/14/01		
PL	A69	FR	1398224			3/29/65		Trans.
PL	A70	FR	1599772			8/1970		Trans.
PL	A71	FR	2689397			10/8/93		Trans.
PL	A72	FR	809691			3/4/59		
PL	A73	FR	835473			5/18/60		
PL	A74	JP	6229570			7/2/87		Trans.

Examiner Signature		Date Considered	12/17/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: December 24, 2003

(use as many sheets as necessary)

Sheet

5

of

11

Complete If Known

Application Number	-Unassigned 10/743909
Filing Date	12/24/2003
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	-Unassigned 1626
Examiner Name	-Unassigned R. Anderson

Attorney Docket Number 034536-0920

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
RA	A75	JP	6239564			2/20/87		Trans.
RA	A76	JP	63141955			6/14/88		Trans.
RA	A77	JP	558894			3/9/93		Trans.
RA	A78	CA	2012634			9/20/91		
RA	A79	AU	286870			5/11/67		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RA	A80	Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," <u>Anticancer Research</u> 16:3585-3588 (1996) 8 Elsevier, Paris	
RA	A81	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)	
RA	A82	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993) 8 Elsevier, Paris	
RA	A83	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992) 8 Elsevier, Paris	
RA	A84	Andreani et al., "Synthesis and potential coanthracycline activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997) 8 Elsevier, Paris	
RA	A85	Andreani et al., "Synthesis of lactams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)	
RA	A86	Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998) 8	
RA	A87	Bahner and Brotherton, "9-(4-Aminobenzylidene)fluorenes," <u>J. Med. Chem.</u> 12:722-723 (1969)	

Examiner Signature

Date Considered

12/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 101743909
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	6	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned R. Anderson
				Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RA	A88	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)	
RA	A89	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> 1028-1030 (1966) 8	
RA	A90	Borsche et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)	
RA	A91	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)	
RA	A92	Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted <i>trans</i> -3-Benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> : 469-473 (1973)	
RA	A93	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin Trans. II</u> : 615-619 (1984)	
RA	A94	Coda et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," <u>Journal of the Chemical Society, Perkin Transactions 2</u> 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21	
RA	A95	Decodts et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," <u>Eur. J. Med. Chem</u> 18: 107-111 (1983)	
RA	A96	Desimoni et al., "Catalysis with Inorganic Cations. V ¹ Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemosselectivity," <u>Tetrahedron</u> 52(36) 12009-12018 (1196) 8 Pergamon	

Examiner Signature 	Date Considered	12/17/04
--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 10/74390A
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	7	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned R Anderson
				Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RA	A97	Elliott and Rivers, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," <u>J. Med. Chem.</u> 29:2438-2440 (1964)	
RA	A98	Elliott et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24	
RA	A99	Gazit et al., "Tyrphostins. 2. Heterocyclic and α -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Clem. Soc.	
RA	A100	Hirao et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," <u>Tetrahedron Letters</u> 36(35) 1995 8Pergamon	
RA	A101	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)	
RA	A102	Howard, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	
RA	A103	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1 <i>H</i>)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992) 8 Elsevier, Paris	
RA	A104	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)	
RA	A105	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97:1033-1039 (1977)	

Examiner Signature		Date Considered	12/17/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 10/743909
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	8	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned K Anderson
				Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>KA</i>	A106	Kovac and Stetinova, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoindoles," <u>Chem. ryesu</u> 30:484-492 (1976)			
<i>KA</i>	A107	Levitzki and Gazit, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)			
<i>KA</i>	A108	Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)			
<i>KA</i>	A109	Mohammadi et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) 8 American Association for the Advancement of Science			
<i>KA</i>	A110	Neber and Röcker, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," <u>Chem. Ber.</u> 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)			
<i>KA</i>	A111	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)			
<i>KA</i>	A112	O'Sullivan and Rotherapy, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975) 8 Elsevier Scientific Publishing Company			
<i>KA</i>	A113	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr Rsrss. Ser. B: Geol., Khim., Biol. Nauki</u> 7:64-66 (1980)			
<i>KA</i>	A114	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7:334-339 (1994)			

Examiner Signature	<i>Malcolm Wilson MOON</i>	Date Considered	12/17/04
--------------------	----------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned 101743909
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	9	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned R. Anderson
				Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>RA</i>	A115	Quallich et al., "A General Oxindole Synthesis," <u>J. Synthetic Organic Chemistry</u> : 51-51 (1993)			
<i>RA</i>	A116	Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)			
<i>RA</i>	A117	Shiraishi et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987) Academic Press			
<i>RA</i>	A118	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives <i>in Vitro</i> ," <u>Cancer Research</u> 49:2374-2378 (1989)			
<i>RA</i>	A119	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena			
<i>RA</i>	A120	Spada, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) 8Ashley Publications			
<i>RA</i>	A121	Sun et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidienyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>Journal of Medicinal Chemistry</u> 42: 5120-5130 (1999) 8American Chemical Society			
<i>RA</i>	A122	Sun et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) 8The American Chemical Society			
<i>RA</i>	A123	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)			

Examiner Signature	<i>Leanne Anderson</i>	Date Considered	12/17/04
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	-Unassigned- 10174390A
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
Sheet	10	of	11	First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned- 1626
				Examiner Name	Unassigned R. Anderson
				Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>RA</i>	A124	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> 150-154 (1976)	
<i>RA</i>	A125	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> 1835-1837 (1993)	
<i>RA</i>	A126	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) 8 Ashley Publications Ltd.	
<i>RA</i>	A127	Wahl et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290	
<i>RA</i>	A128	Wahl, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)	
<i>RA</i>	A129	Wahl, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)	
<i>RA</i>	A130	Walker et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β -Alkylaminooethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)	
<i>RA</i>	A131	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Am. Chem. Soc.</u> 78:221-224 (1956)	
<i>RA</i>	A132	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	

Examiner Signature	<i>Lehman Anderson</i>	Date Considered	12/17/04
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned - 1017439 CP
Date Submitted: December 24, 2003 (use as many sheets as necessary)				Filing Date	12/24/2003
				First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned - R Anderson
Sheet	11	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RA	A133	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) copyright The American Society for Pharmacology and Experimental Pharmacetics	
RA	A134	Zhungetu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Chemical Abstracts</u> , Vol. 78, abstract no. 111201 (1990)	

Examiner Signature		Date Considered	12/17/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/743,909</td> </tr> <tr> <td>Filing Date</td> <td>12/24/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Malcolm Wilson Moon</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>034536-0920</td> </tr> </table>		Application Number	10/743,909	Filing Date	12/24/2003	First Named Inventor	Malcolm Wilson Moon	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	034536-0920
Application Number	10/743,909																
Filing Date	12/24/2003																
First Named Inventor	Malcolm Wilson Moon																
Group Art Unit	Unassigned																
Examiner Name	Unassigned																
Attorney Docket Number	034536-0920																
Sheet	1	of	1														

U.S. PATENT DOCUMENTS

Examiner Signature		Date Considered	11/5/04
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO)

⁴Unique Citation Designation Number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.